Scandion Oncology A/S (“Scandion” or the “Company”) has completed the first 12 patient cohort in the ongoing dose-range finding part of the clinical phase II study with SCO-101 in combination with chemotherapy (FOLFIRI) in patients with drug resistant metastatic colorectal cancer. The Company has now received green light from the Data Safety Monitoring Board to move forward with the next treatment cohorts.
In this first cohort from the CORIST study, all patients received combination treatment with SCO-101 and the chemotherapy regime FOLFIRI. The cohort was utilized to stepwise adjust the dose of chemotherapy when given together with a fixed dose of SCO-101.
First cohort has added significant understanding
CMO Peter Michael Vestlev: “The CORIST study is our first clinical study where SCO-101 is combined with chemotherapy in drug resistant cancer patients who have no further treatment options. The data has added significant understanding of how to proceed with the SCO-101 treatment. I am looking forward to the next cohorts and to perform the second part of this phase II clinical study.”
Timeline maintained, readout expected in Q2, 2021
CEO Bo Rode Hansen: “Our clinical team together with the clinical investigators have done a great job in recruiting this many patients within a short time frame despite the COVID-19 situation. We maintain our expectation of a readout in Q2, 2021 from this first part of the CORIST study.”
For further information, please contact:
Bo Rode Hansen, CEO
Phone: +45 38 10 20 17
This information is information that Scandion Oncology A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on 23 January 2021.
About Scandion Oncology
Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. The Company is conducting a list change from Spotlight to Nasdaq First North Growth Market Sweden in February 2021. Ticker code: SCOL.